<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04682158</url>
  </required_header>
  <id_info>
    <org_study_id>I 630420</org_study_id>
    <nct_id>NCT04682158</nct_id>
  </id_info>
  <brief_title>Propranolol With Standard Chemoradiation for Esophageal Adenocarcinoma</brief_title>
  <official_title>Propranolol With Standard Chemoradiation for Esophageal Adenocarcinoma A Phase II Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Roswell Park Cancer Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Roswell Park Cancer Institute</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This phase II trial studies the side effects and best dose of propranolol when administered&#xD;
      concurrently with SOC neoadjuvant CRT in patients with esophageal carcinoma, with a safety&#xD;
      lead-in and dose expansion cohort. Patients who are already on Î²-blockers will receive&#xD;
      standard of care CRT and will be considered separately as a single arm prospective cohort&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVE:&#xD;
&#xD;
      I. To determine the safety and efficacy of propranolol hydrochloride (propranolol) in&#xD;
      combination with standard neoadjuvant/definitive chemoradiation therapy (CRT) for esophageal&#xD;
      cancer.&#xD;
&#xD;
      SECONDARY OBJECTIVE:&#xD;
&#xD;
      I. To estimate overall survival (OS) and pathologic response rate in patients that undergo&#xD;
      surgery.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 1, 2021</start_date>
  <completion_date type="Anticipated">April 1, 2024</completion_date>
  <primary_completion_date type="Anticipated">April 1, 2023</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Occurrence of Adverse Events</measure>
    <time_frame>Up to 5 years</time_frame>
    <description>To determine the safety and efficacy of the combination of propranolol plus chemoradiation</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Progression Free Survival</measure>
    <time_frame>UP to 5 years</time_frame>
    <description>Imaging findings from first radiation treatment to progression of disease</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>Up to 5 years</time_frame>
    <description>will be assessed by chart review of date of last follow-up or date of death</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Esophageal Adenocarcinoma</condition>
  <arm_group>
    <arm_group_label>Chemoradiation Therapy - Group I</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients receiving beta-blockers undergo radiation therapy in the form of IMRT or 3D CRT over 23-28 fractions for 5 days per week (Monday-Friday) for 5 weeks, and receive paclitaxel IV QW and carboplatin IV QW for 5 weeks in the absence of disease progression or unacceptable toxicity.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Chemoradiation Therapy - Group II</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients undergo CRT as in Group I in the absence of disease progression or unacceptable toxicity.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Chemoradiation Therapy plus Propanolol</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients undergo radiation therapy as in Group I. Patients receive propranolol PO BID for 4-6 weeks while receiving CRT in the absence of disease progression or unacceptable toxicity.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Carboplatin</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Chemoradiation Therapy - Group I</arm_group_label>
    <other_name>(SP-4-2)-diammine[1,1-cyclobutanedicarboxylato(2--)-O,O'']platinum</other_name>
    <other_name>Blastocarb</other_name>
    <other_name>CBDCA</other_name>
    <other_name>Displata</other_name>
    <other_name>Ercar</other_name>
    <other_name>JM-8</other_name>
    <other_name>Nealorin</other_name>
    <other_name>Novoplatinum</other_name>
    <other_name>Paraplatin</other_name>
    <other_name>Ribocarbo</other_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>3 Dimensional Conformal Radiation Therapy</intervention_name>
    <description>Undergo 3D CRT</description>
    <arm_group_label>Chemoradiation Therapy - Group I</arm_group_label>
    <arm_group_label>Chemoradiation Therapy - Group II</arm_group_label>
    <arm_group_label>Chemoradiation Therapy plus Propanolol</arm_group_label>
    <other_name>3D-CRT</other_name>
    <other_name>Radiation</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Propranolol</intervention_name>
    <description>Subject will be treated with 30 mg po BID Propranolol for up to 6 weeks</description>
    <arm_group_label>Chemoradiation Therapy plus Propanolol</arm_group_label>
    <other_name>2-Propanol-1-[(1-methylethyl)amino]-3-(1-naphthalenyloxy) Hydrochloride</other_name>
    <other_name>318-98-9</other_name>
    <other_name>Inderal</other_name>
    <other_name>Innopran XL</other_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Intensity Modulated Radiation Therapy</intervention_name>
    <description>Undergo IMRT</description>
    <arm_group_label>Chemoradiation Therapy - Group I</arm_group_label>
    <arm_group_label>Chemoradiation Therapy plus Propanolol</arm_group_label>
    <other_name>IMRT</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Paclitaxel</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Chemoradiation Therapy - Group I</arm_group_label>
    <other_name>33069-62-4</other_name>
    <other_name>5Beta,20-epoxy-1,2alpha</other_name>
    <other_name>Anzatax</other_name>
    <other_name>Bristaxol</other_name>
    <other_name>Praxel</other_name>
    <other_name>Taxol</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Undergoing definitive or neoadjuvant CRT for histologically confirmed esophageal&#xD;
             adenocarcinoma&#xD;
&#xD;
          -  Have an ECOG performance status of 0-1&#xD;
&#xD;
          -  Have the ability to swallow and retain oral medication. If a patient is not able to&#xD;
             swallow, they are still eligible for study provided they have an enteric feeding&#xD;
             placed which will permit administration of liquid formula propranolol prior to first&#xD;
             radiation treatment&#xD;
&#xD;
          -  Participants of child-bearing potential must have a negative pregnancy test at study&#xD;
             entry And then agree to use adequate contraceptive methods (e.g., hormonal or barrier&#xD;
             method of birth control; abstinence) prior to study entry. - Should a woman become&#xD;
             pregnant or suspect she is pregnant while she or her partner is participating in this&#xD;
             study, she should inform her treating physician immediately.&#xD;
&#xD;
          -  Participant must understand the investigational nature of this study and sign an&#xD;
             Independent Ethics Committee/Institutional Review Board approved written informed&#xD;
             consent form prior to receiving any study related procedure.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Contraindications to the use of beta-blockers, e.g.; uncontrolled depression, unstable&#xD;
             angina pectoris, uncontrolled heart failure (New York Heart Association (NYHA) Grade&#xD;
             III or IV), hypotension ( systolic blood pressure &lt;100 mmHg), severe asthma or COPD,&#xD;
             uncontrolled type I or type II diabetes mellitus (HbA1C &gt;8.5 or fasting plasma glucose&#xD;
             &gt; 160 mg/dL at screening), symptomatic peripheral arterial disease or Raynaud's&#xD;
             syndrome, untreated pheochromocytoma, current calcium channel blocker use&#xD;
             (Non-dihydropyridines such as verapamil) or rhythm control agents such as digoxin and&#xD;
             amiodarone. Patients with pacemakers will be excluded&#xD;
&#xD;
          -  Uncontrolled intercurrent illness including, but not limited to, ongoing or active&#xD;
             infection,symptomatic congestive heart failure, unstable angina pectoris, psychiatric&#xD;
             illness/social situations that would limit compliance with study requirements, cardiac&#xD;
             arrhythmia (atrial fibrillation/flutter), severe bradycardia (heart rate of &lt;50 beats&#xD;
             per minute or 1st/ 2nd /3rd degree heart block)&#xD;
&#xD;
          -  Pregnant or nursing female participants,&#xD;
&#xD;
          -  Unwilling or unable to follow protocol requirements&#xD;
&#xD;
          -  Any condition which in the Investigator's opinion deems the participant an unsuitable&#xD;
             candidate to receive study drug&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Anurag Singh, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Roswell Park Cancer Institute</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>ASK RPCI</last_name>
    <phone>1-800-767-9355</phone>
    <email>askroswell@roswellpark.org</email>
  </overall_contact>
  <location>
    <facility>
      <name>Roswell Park Cancer Institute</name>
      <address>
        <city>Buffalo</city>
        <state>New York</state>
        <zip>14263</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>December 21, 2020</study_first_submitted>
  <study_first_submitted_qc>December 21, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">December 23, 2020</study_first_posted>
  <last_update_submitted>November 11, 2021</last_update_submitted>
  <last_update_submitted_qc>November 11, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 12, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Adenocarcinoma</mesh_term>
    <mesh_term>Esophageal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Carboplatin</mesh_term>
    <mesh_term>Propranolol</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

